What is PathoGenetix?
PathoGenetix, Inc. is at the forefront of developing an automated system designed for the rapid identification of bacteria from complex biological samples. The company's core innovation, Genome Sequence Scanning (GSS) technology, offers a groundbreaking approach by isolating and analyzing DNA directly from an enriched sample without the necessity of a cultured isolate. This method drastically reduces analysis time, delivering results in approximately five hours, a significant improvement over traditional methods that can take days. The GSS technology holds broad applicability across critical sectors including food safety, industrial microbiology, and clinical diagnostics and research. PathoGenetix has previously garnered substantial technology development funding, exceeding $50 million, from the Department of Homeland Security, highlighting the critical nature of its work.
How much funding has PathoGenetix raised?
PathoGenetix has raised a total of $24.2M across 5 funding rounds:
Series A
$4.4M
Debt
$1M
Unspecified
$1.3M
Series B
$7.5M
Series C
$10M
Series A (2008): $4.4M, investors not publicly disclosed
Debt (2010): $1M, investors not publicly disclosed
Unspecified (2010): $1.3M, investors not publicly disclosed
Series B (2011): $7.5M featuring Ascension Ventures, Frazier Healthcare Ventures, and Excel Venture Management
Series C (2013): $10M backed by Ascension Ventures, Excel Venture Management, and HealthCare Ventures
Key Investors in PathoGenetix
Ascension Ventures
Ascension Ventures is a strategic healthcare venture firm that invests on behalf of leading community health systems, focusing on companies transforming the healthcare industry.
Frazier Healthcare Ventures
Frazier Healthcare Ventures is a venture capital firm with a focus on the healthcare sector, investing in companies developing innovative treatments and technologies.
Excel Venture Management
Excel Venture Management is a venture capital firm that invests in companies with high growth potential, often in technology and healthcare sectors.
What's next for PathoGenetix?
With the recent strategic investment and a substantial total funding history, PathoGenetix is well-positioned for its next phase of growth. The company's focus on accelerating the availability of its first commercial GSS system for food safety testing and outbreak investigations indicates a clear path toward market impact. Future developments will likely involve scaling production, expanding its commercial reach, and potentially exploring new applications for its rapid diagnostic technology in clinical settings. The ongoing backing from strategic investors suggests confidence in PathoGenetix's ability to address urgent needs in public health and safety through advanced molecular diagnostics.
See full PathoGenetix company page
